Thus, the combination of TLR9 stimulation and PD-1 blockade reshapes macrophages into a more suppressive, tumor-promoting state, limiting the potential therapeutic benefit of this regimen in ovarian cancer (156). Here, TLR9 is linked to ovarian carcinoma.